CC10 administration to premature infants: In search of the "silver bullet" to prevent lung inflammation

Pediatric Research

Volumn 58, Issue 1, 2005, Pages 7-9

  Welty, Stephen E ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CC 10; CLARA CELL PROTEIN;

ANTIINFLAMMATORY ACTIVITY; CLARA CELL; DRUG EFFECT; DRUG ELIMINATION; DRUG MECHANISM; DRUG SAFETY; HUMAN; INFANT; LUNG DYSPLASIA; NEUTROPHIL; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PNEUMONIA; PREMATURITY; PRIORITY JOURNAL;

BRONCHOPULMONARY DYSPLASIA; CLINICAL TRIALS; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INFLAMMATION; LUNG; LUNG DISEASES; NEUTROPHILS; OXIDATIVE STRESS; PNEUMONIA; RESPIRATORY DISTRESS SYNDROME, NEWBORN; TIME FACTORS; UTEROGLOBIN;

EID: 22044456813     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/01.PDR.0000163373.65809.F5     Document Type: Note

References (24)

1. Levine C, Gewolb, IH, Allen K, Welch RW, Melby JM, Pollack S, Shaffer T, Pilon AL, Davis JM 2005 The Safety, Pharmacokinetics and Anti-Inflammatory Effects of Intratracheal Recombinant Human Clara Cell Protein in Premature Infants with Respiratory Distress Syndrome. Pediatr Res 58:15-21
2. Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ, Verier J, Temprosa M, Wright LL, Ehrenkranz RA, Fanaroff AA, Stark A, Carlo W, Tyson JE, Donovan EF, Shankaran S, Stevenson DK 2001 Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 107:E1
3. Koumbourlis AC, Motoyama EK, Mutich RL, Mallory GB, Walczak SA, Fertal K 1996 Longitudinal follow-up of lung function from childhood to adolescence in prematurely born patients with neonatal chronic lung disease. Pediatr Pulmonol 21:28-34
4. Mallory GB Jr, Chaney H, Mutich RL, Motoyama EK 1991 Longitudinal changes in lung function during the first three years of premature infants with moderate to severe bronchopulmonary dysplasia. Pediatr Pulmonol 11:8-14
5. Vohr BR, Wright LL, Dusick AM, Mele L, Veiter J, Steichen JJ, Simon NP, Wilson DC, Broyles S, Bauer CR, Delaney-Black V, Yolton KA, Fleisher BE, Papile LA, Kaplan MD 2000 Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994. Pediatrics 105:1216-1226
6. Groneck P, Gotze-Speer B, Oppermann M, Eiffert H, Speer CP 1994 Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates. Pediatrics 93:712-718
7. Viscardi RM, Muhumuza CK, Rodriguez A, Fairchild KD, Sun CC, Gross GW, Campbell AB, Wilson PD, Hester L, Hasday JD 2004 Inflammatory markers in intrauterine and fetal blood and cerebrospinal fluid compartments are associated with adverse pulmonary and neurologic outcomes in preterm infants. Pediatr Res 55:1009-1017
8. Munshi UK, Niu JO, Siddiq MM, Parton LA 1997 Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. Pediatr Pulmonol 24:331-336
9. Ramsay PL, O'Brian Smith E, Hegemier S, Welty SE 1998 Early clinical markers for the development of bronchopulmonary dysplasia: soluble E-selectin and ICAM-1. Pediatrics 102:927-932
10. Halliday HL, Ehrenkranz RA, Doyle LW 2003 Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 1: CD001146
11. Farrow J, Melby J, Wiese L, Lohnas J, Welch R, Pilon AL 2000 Binding of rhCC10 to fibronectin and its effect on cellular adhesion. Ann N Y Acad Sci 923:338-342
12. Yoshikawa S, Miyahara T, Reynolds SD, Stripp BR, Anghelescu M, Eyal FG, Parker JC 2005 Clara cell secretory protein and phospholipase A2 activity modulate acute ventilator-induced lung injury in mice. J Appl Physiol 98:1264-1271
13. Jorens PG, Sibille Y, Goulding NJ, van Overveld FJ, Herman AG, Bossaert L, De Backer WA, Lauwerys R, Flower RJ, Bernard A 1995 Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury. Eur Respir J 8:1647-1653
14. Hayashida S, Harrod KS, Whitsett JA 2000 Regulation and function of CCSP during pulmonary Pseudomonas aeruginosa infection in vivo. Am J Physiol Lung Cell Mol Physiol 279:L452-L459
15. Harrod KS, Mounday AD, Stripp BR, Whitsett JA 1998 Clara cell secretory protein decreases lung inflammation after acute virus infection. Am J Physiol 275:L924-L930
16. Wang SZ, Rosenberger CL, Bao YX, Stark JM, Harrod KS 2003 Clara cell secretory protein modulates lung inflammatory and immune responses to respiratory syncytial virus infection. J Immunol 171:1051-1060
17. Lassus P, Nevalainen TJ, Eskola JU, Andersson S 2000 Clara-cell secretory protein in preterm infants' tracheal aspirates correlates with maturity and increases in infection. Pediatr Pulmonol 30:466-469
18. Ramsay PL, DeMayo FJ, Hegemier SE, Wearden ME, Smith CV, Welty SE 2001 Clara cell secretory protein oxidation and expression in premature infants who develop bronchopulmonary dysplasia. Am J Respir Crit Care Med 164:155-161
19. Watterberg KL, Carmichael DF, Gerdes JS, Werner S, Backstrom C, Murphy S 1994 Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia. J Pediatr 125:264-269
20. Rosenfeld WN, Davis JM, Parton L, Richter SE, Price A, Plaster E, Kassem N 1996 Safety and pharmacokinetics of recombinant human superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics 97:811-817
21. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W 2003 Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 111:469-476
22. Vohr BR, Wright LL, Dusick AM, Perritt R, Poole WK, Tyson JE, Steichen JJ, Bauer CR, Wilson-Costello DE, Mayes LC 2004 Center differences and outcomes of extremely low birth weight infants. Pediatrics 113:781-789
23. Watts CL, Fanaroff AA, Bruce MC 1992 Elevation of fibronectin levels in lung secretions of infants with respiratory distress syndrome and development of bronchopulmonary dysplasia. J Pediatr 120:614-620
24. Hite RD, Seeds MC, Safta AM, Jacinto RB, Gyves JI, Bass DA, Waite BM 2005 Lysophospholipid generation and phosphatidylglycerol depletion in phospholipase A(2)-mediated surfactant dysfunction. Am J Physiol Lung Cell Mol Physiol 288:L618-L624